Lottomatica Shorts Rebuild as CIRSA Deal Reshapes the Float

Lottomatica has had a strong week, up 6% to EUR 28.41, but the most interesting development is not the price gain. It is what is happening beneath it: short interest is rebuilding sharply, borrowing demand has jumped, and the agreed takeover of Cirsa Enterprises is bringing index tracker flows into the picture. The setup is more complex than the headline return suggests.

The lending market tells the most striking story this week. Availability has tightened dramatically. At the start of October, more than 2,000% of short interest was available to borrow, a genuinely loose market with little short-selling pressure. By November 10 that figure had collapsed to 144%, the tightest reading of the past year. In practical terms, for every share currently shorted, only about 1.4 shares remain available to lend. That is still comfortably above a squeeze threshold, but the direction of travel is sharp: availability fell 54% in one week alone. Cost to borrow remains low at 0.80%, down around 11% over the past month, so the tightening is about demand for borrows rising rather than any structural change in supply. The ORTEX short score, an aggregated signal of short-selling pressure, has climbed from 55 in late October to 69.3 as of November 10, the highest reading in the available history. The score's acceleration in the final week of the series is the clearest sign that positioning is shifting.

The Street, however, is unambiguously bullish. All 12 analyst recommendations tracked by ORTEX are buys, with no neutral or sell ratings in the mix. The mean price target of EUR 33.08 implies roughly 16% upside to the current price. The analyst consensus factor score ranks in the 94th percentile of the coverage universe, the highest of any score in the profile. The dividend score at the 92nd percentile adds further support for income-oriented holders. Valuation is not cheap: the price-to-book ratio is elevated at 33.7, and the PE of 13.2x has risen about 1.9 points over the past 30 days as the stock has moved up. EV/EBITDA sits near 8.4x. The short-score rank, though, falls in just the 9th percentile, meaning the ORTEX model flags this as a name with meaningful short-selling pressure relative to peers, a contrast with the uniformly positive analyst view.

The key structural catalyst is the agreed acquisition of CIRSA. Because Lottomatica is paying in stock, the deal will increase the share count. ORTEX forecasts an 85% probability that the enlarged float triggers a share-count increase in the STOXX Europe 600 and STOXX Europe 600 Eurozone indices, requiring index trackers to buy an estimated $15 million and $8 million respectively. The FTSE MIB rebalance carries a 65% probability and an estimated $30 million of tracker buying. All three are classified as forecasts; the index providers have not confirmed them. Estimated announcement dates cluster around late June 2027, with effective dates around June 30. The rebuilding short interest in the near term may partly reflect arbitrage activity around the deal mechanics, with some participants hedging the share-count dilution from the stock consideration.

FMR (Fidelity) is the largest active institutional holder with 9.8% of shares, having added around 511,000 shares to its position as of August. DNCA Finance disclosed a large increase of 3.1 million shares to reach 3.3% as of June. Boston Partners effectively built a new position of 3.75 million shares over the same period. Insider activity from June is classified as stale at 146 days old and all trades were coded as "Other" rather than open-market purchases or sales, so they carry limited signal value.

The next earnings event is not scheduled until March 2027, leaving several months before the fundamental narrative is tested again. In the near term, what to watch is whether the sharp tightening in borrow availability continues, and whether ORTEX's index rebalance probabilities are revised as more clarity emerges on the CIRSA deal timeline and final share count.